MétaCan
Menu
← Back to cohort
Record W4205610220 · doi:10.1002/alz.056094

[11C]PiB and [18F]AV45 PET radiotracers show different rates of amyloid‐β clearance

2021· article· en· W4205610220 on OpenAlexaff
Charles D. Chen, Austin McCullough, Brian A. Gordon, Nelly Joseph‐Mathurin, Guoqiao Wang, Yan Li, Chengjie Xiong, Michael J. Pontecorvo, Gregory Klein, Sergey Shcherbinin, Ixavier A. Higgins, Colin L. Masters, David B. Clifford, Christopher H. van Dyck, Mario Masellis, Ging‐Yuek Robin Hsiung, Serge Gauthier, Randall J. Bateman, Eric McDade, Stephen Salloway, Tammie L.S. Benzinger

Bibliographic record

VenueAlzheimer s & Dementia · 2021
Typearticle
Languageen
FieldMedicine
TopicAlzheimer's disease research and treatments
Canadian institutionsDouglas Mental Health University InstituteHealth Sciences CentreSunnybrook Health Science Centre
Fundersnot available
KeywordsNuclear medicineStandardized uptake valuePittsburgh compound BMedicinePositron emission tomographyInternal medicineCognitive impairmentDisease

Abstract

fetched live from OpenAlex

Abstract Background Results from the first Dominantly Inherited Alzheimer Network Trials Unit (DIAN‐TU) clinical trial showed Gantenerumab reduces amyloid‐β deposition in autosomal dominant Alzheimer disease individuals. However, it is uncertain whether these initial findings from [11C]PiB PET generalize to other amyloid‐β PET radiotracers. Method We acquired [11C]PiB and [18F]AV45 PET in mutation positive DIAN‐TU participants in the gantenerumab (n=30) and placebo drug arms (n=19). Participants were assessed at baseline and Year 4; at each visit, [11C]PiB and [18F]AV45 PET were acquired, with at most 28 days between imaging sessions. Regional standardized uptake value ratios (SUVRs) were quantified using the PET Unified Pipeline. Annualized SUVR percent change between baseline and Year 4 for both radiotracers in both drug arms were calculated. Differences in SUVR change between radiotracers/drug arms were assessed using the Wilcoxon signed‐rank/rank‐sum test. Each test statistic is reported as a rank‐biserial correlation r accompanied by p‐values adjusted for false discovery control by the Benjamini‐Hochberg procedure at level q=0.20. Result We observed a decrease from baseline to Year 4 SUVR in the gantenerumab arm, which was larger when studied with [11C]PiB than with [18F]AV45 PET in several regions, including the striatum and cingulate gyrus (r=[‐0.79,‐0.31], FDR‐adjusted p‐values=[0.00086,0.19], Figure 1). In contrast, we observed an increase in SUVR in the placebo arm, comparable in magnitude between [11C]PiB and [18F]AV45 PET (r=[‐0.15,0.68], FDR‐adjusted p‐values=[0.29,0.86]). Conclusion Differences seen between the effects of gantenerumab in [11C]PiB versus [18F]AV45 PET suggest several regions, such as the striatum and cingulate gyrus, may be inappropriate for radiotracer harmonization in studies involving gantenerumab. More practically, the finding that anti‐amyloid‐β therapies may have different effects on signal across radiotracers suggests multi‐site studies of anti‐amyloid‐β treatments should agree on a single radiotracer for best results. Follow‐up postmortem studies will be conducted to determine the binding affinity of various amyloid‐β radiotracers to amyloid‐β plaques in this cohort.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.017

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.003
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.032
GPT teacher head0.313
Teacher spread0.281 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicAlzheimer's disease research and treatments→French-language works237,207→